project id: TCGA-PRAD; case submitter id: TCGA-G9-6361; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wxs: false; state: released; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.13; rna integrity number: 7.9; age at index: 61; days to birth: -22565; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1948; age at diagnosis: 22565; ajcc clinical m: M0; ajcc clinical t: T2c; ajcc pathologic n: N0; ajcc pathologic t: T3a; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 1415.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 3; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 4; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2009; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to sample procurement: 0; intermediate dimension: 0.7; longest dimension: 1.3; oct embedded: No; shortest dimension: 0.2; portion submitter id: TCGA-G9-6361-01A-21; percent lymphocyte infiltration: 2.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 10.0; percent stromal cells: 20.0; percent tumor cells: 70.0; percent tumor nuclei: 70.0;